NCT05230810 2026-03-16Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Criterium, Inc.Phase 1/2 Active not recruiting40 enrolled
NCT05382364 2026-03-12Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)PfizerPhase 1 Active not recruiting25 enrolled
NCT03975647 2025-12-10A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeagen Inc.Phase 3 Active not recruiting466 enrolled 17 charts